New Macromolecular Drug Born in Shenzhen
After more than a decade, the research team led by WAN Xiaochun, the deputy director of the Institute of Biomedicine and Biotechnology of SIAT, has finally developed an original macromolecule drug, AS1501, which is suitable for liver damage and liver failure caused by viral, autoimmune and drug-induced hepatitis.
Before returning home from abroad, Prof. WAN had been engaged in the research of antibody drugs for more than 20 years in foreign scientific research institutes and large pharmaceutical companies, mainly in the research and development of therapeutic antibody drugs and autoimmune diseases. Domestic researchers have been aware of the fact that in recent years, China is still subject to generic drug development, and that the need for large amounts of funding and strict approval procedures make it difficult for researchers to see the light of day. To this end, Prof. WAN decided to engage in new drug research and development, and to participate in the innovation team to develop the new generation of monoclonal antibody drug.
Prof. WAN has more than 20 years of experience in monoclonal antibody research and is also the inventor of the patent technology for pure human monoclonal antibody. Wan's team found that hepatitis caused mass death of stem cells, including five death receptors "what we need to do is turn off the death switch so the stem cells won’t die." He further explained that AS1501 competes with DR5 on the surface of cell membrane to bind TRAIL, thus blocking the binding of TRAIL and DR5 on the surface of cell membrane to produce cell apoptosis, which plays a role in protecting liver cells and resisting liver cell apoptosis.
Compared with the existing drugs for liver diseases in the market, AS1501 focuses on organ damage caused by host immune response on the basis of etiology and treatment, and blocks cell death, thus effectively organizing liver injury and liver failure. Through research, Wan’s team found that AS1501, as a frontal blocker of apoptosis, not only targeted at liver failure, but also had good effects on myocardial infarction, myocardial ischemia reperfusion injury, cerebral stroke, chronic obstructive pulmonary disease, sepsis, Alzheimer's disease, etc., which needs further verification and is expected to be promoted to clinical application in the future.
Developing the new drug is by no means an easy task for Wan’s team. He claims the innovation team on the next generation of monoclonal antibody drug will continue to focus on monoclonal antibody drug research and development. He believes by improving the independent innovation ability of monoclonal antibody drug research and development, they can ultimately beef up the competitiveness of China's pharmaceutical industry.
Experiment in progress